Adverse events and safety
hyperkalemia
The changes in the mean arterial pressure from baseline to week 24 were 1.67 ± 17.13 mmHg in the roxadustat group and 3.82 ± 11.68 mmHg in the ESA group (difference, − 2.14 mmHg; 95% CI, − 8.45 to 4.16). Although no difference was found in the proportion of patients who did not achieve the control goal (roxadustat, 64.29%; ESA, 69.44%), a higher proportion of patients in the ESA group increased or adjusted blood pressure medication (roxadustat, 25.47%; ESA, 47.17%).Roxadustat did not increase the incidence of hyperkalemia (High-sensitivity C-reactive protein levels in the roxadustat (